{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.7"},{"groupId":"OG001","value":"98.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"151"}],"units":"Participants"}],"description":"An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.","groups":[{"description":"Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"OG000","title":"Alectinib"},{"description":"Participants received crizotinib at 250 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"OG001","title":"Crizotinib"}],"paramType":"NUMBER","populationDescription":"Safety (SAF) population included all participants who received at least one dose of any study drug.","reportingStatus":"POSTED","timeFrame":"Baseline up to approximately 10 years","title":"Percentage of Participants With Adverse Events","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}